PHOENIX ― Gastrointestinal cancers are some of the most commonly diagnosed cancers, and they continue to be associated with poor survival outcomes. The drug adagrasib specifically targets the KRASG12C gene mutation that is common in gastrointestinal cancers and inhibits gastrointestinal function.
Trending
- AI adoption surges, but providers worry about deskilling (Healthcare Dive)
- The gastroenterologist pay gap (Becker’s GI & Endoscopy)
- 8 No Surprises Act shake-ups physicians need to know (Becker’s Healthcare)
- ChristianaCare researchers identify genetic drivers of aggressive CRC (Becker’s GI & Endoscopy)
- A Collaborative Approach for Advanced IBD Therapy Prior Authorization Denials (GI & Endoscopy News)
- Personalized Nutrition: The Future of Gastroenterology (Grand View Research)
- Mindray Leads the Evolution of Gastroenterology Imaging with the Newly Expanded Hepatus-Series Ultrasound Systems (PR Newswire)
- How NYU Langone is helping modernize a decades-old GI surgery tool (Becker’s GI & Endoscopy)
